Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.

abstract：:With the use of combination chemotherapy as well as a wide range of symptomatic therapies (e.g. analgesics and antiemetics) for the treatment of patients with cancer, the field of oncology practises polypharmacy to an extreme degree. The risk for a drug interaction under these conditions is high, and the pharmacologic...

journal_title：Clinical pharmacokinetics

authors： Balis FM

更新日期：1986-05-01 00:00:00

abstract：:Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

journal_title：Clinical pharmacokinetics

authors： Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

更新日期：1986-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:A simple approach is proposed to predict drug clearance in children when no paediatric data are available for drugs metabolised by cytochromes. METHODS:The maturation functions of cytochrome activity and binding proteins in plasma were combined with several measures of body size to describe dr...

journal_title：Clinical pharmacokinetics

authors： Cerruti L,Bleyzac N,Tod M

更新日期：2018-07-01 00:00:00

abstract：:Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

journal_title：Clinical pharmacokinetics

authors： Michalets EL,Williams CR

更新日期：2000-07-01 00:00:00

abstract：:According to recent clinical consensus, pharmacotherapy of inflammatory bowel disease (IBD) is, or should be, personalized medicine. IBD treatment is complex, with highly different treatment classes and relatively few data on treatment strategy. Although thorough evidence-based international IBD guidelines currently e...

journal_title：Clinical pharmacokinetics

authors： Derijks LJJ,Wong DR,Hommes DW,van Bodegraven AA

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:The imatinib trough plasma concentration (C(min)) correlates with clinical response in cancer patients. Therapeutic drug monitoring (TDM) of plasma C(min) is therefore suggested. In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely...

journal_title：Clinical pharmacokinetics

authors： Gotta V,Widmer N,Montemurro M,Leyvraz S,Haouala A,Decosterd LA,Csajka C,Buclin T

更新日期：2012-03-01 00:00:00

abstract：:Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. Following oral administration, the drug is absorbed efficiently from the gastrointestinal tract. Peak plasma concentrations are usually observed within 2 to 8 hours postdose for capsules and film-coated tabl...

journal_title：Clinical pharmacokinetics

authors： Perucca E,Gatti G,Spina E

更新日期：1994-09-01 00:00:00

abstract：:Obesity is associated with physiological changes that can alter the pharmacokinetic parameters of many drugs. Vancomycin and the aminoglycosides are the only antibacterials that have been extensively investigated in the obese population. The apparent volume of distribution (Vd) and total body clearance of vancomycin a...

journal_title：Clinical pharmacokinetics

authors： Bearden DT,Rodvold KA

更新日期：2000-05-01 00:00:00

abstract：:The plasma protein binding of drugs, particularly those that are highly bound, may have significant clinical implications. Although protein binding is a major determinant of drug action, it is only one of a myriad of factors that influence drug disposition. The extent of protein binding is a function of drug and prote...

journal_title：Clinical pharmacokinetics

authors： Grandison MK,Boudinot FD

更新日期：2000-03-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：:Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20...

journal_title：Clinical pharmacokinetics

authors： Mahmood I,Sahajwalla C

更新日期：1999-04-01 00:00:00

abstract：:Warfarin, like all the 4-hydroxycoumarin compounds, has an asymmetric carbon atom. The clinically available warfarin preparations consist of a racemic mixture of equal amounts of 2 distinct S and R isomers, the former being 4-times more potent as anticoagulant and more susceptible to drug interaction. Warfarin is high...

journal_title：Clinical pharmacokinetics

authors： Palareti G,Legnani C

更新日期：1996-04-01 00:00:00

abstract：:Pharmacological treatment of patients with Alzheimer's disease is becoming more important, as evidenced by the number of drugs being developed in different countries. It has been shown in the majority of clinical trials that cholinesterase inhibitors, such as tacrine (tetrahydroaminoacridine), are able to induce benef...

journal_title：Clinical pharmacokinetics

authors： Parnetti L

更新日期：1995-08-01 00:00:00

abstract：:Fluconazole was recently developed for the treatment of superficial and systemic fungal infections. Triazole groups and insertion of 2 fluoride atoms increase the polarity and hydrosolubility of the drug, allowing it to be used in a parenteral form. Bioassay methods using Candida pseudotropicalis as a test organism we...

journal_title：Clinical pharmacokinetics

authors： Debruyne D,Ryckelynck JP

更新日期：1993-01-01 00:00:00

abstract：:The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism. The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, ...

journal_title：Clinical pharmacokinetics

authors： Dal Negro R,Pomari C,Turco P

更新日期：1993-03-01 00:00:00

abstract：OBJECTIVE:The objective of this analysis was to simulate the performance of oral triptan formulations with varying absorption characteristics and their impact on the onset and magnitude of the antimigraine effect using a Markov model for migraine attacks. ANALYSIS:Sumatriptan pharmacokinetic data were obtained from cl...

journal_title：Clinical pharmacokinetics

authors： Maas HJ,Spruit MA,Danhof M,Della Pasqua OE

更新日期：2008-01-01 00:00:00

abstract：:Uncertainty exists as to the most suitable pharmacokinetic parameter sets for propofol target-controlled infusions (TCI). The pharmacokinetic parameter sets currently employed are clearly not universally applicable, particularly when patient attributes differ from those of the subjects who participated in the original...

journal_title：Clinical pharmacokinetics

authors： Coetzee JF

更新日期：2012-03-01 00:00:00

abstract：:Clarithromycin is a semisynthetic macrolide antibiotic, structurally related to erythromycin. It has a more favourable pharmacokinetic profile than erythromycin, thus allowing twice-daily administration and possibly increasing compliance among outpatients. Clarithromycin is well absorbed from the gastrointestinal trac...

journal_title：Clinical pharmacokinetics

authors： Fraschini F,Scaglione F,Demartini G

更新日期：1993-09-01 00:00:00

abstract：:Routine use of therapeutic drug monitoring in children is helpful in individualizing the dosage during long term treatment (e.g. theophylline and antiepileptic drugs) and in checking against toxic accumulation of drug in neonates (e.g. digoxin, theophylline/caffeine and aminoglycoside antibiotics). In individual patie...

journal_title：Clinical pharmacokinetics

authors： Boréus LO

更新日期：1989-01-01 00:00:00

abstract：:Pregnancy is a specific dynamic state, and the potential usefulness of caring for a disorder in the fetus or the mother is now well established. Previously, pregnant women have been excluded from clinical trials, therefore only a few studies concerning evaluation of the pregestational metabolism or transplacental tran...

journal_title：Clinical pharmacokinetics

authors： Bourget P,Roulot C,Fernandez H

更新日期：1995-02-01 00:00:00

abstract：BACKGROUND:Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics. PATIENTS AND METHO...

journal_title：Clinical pharmacokinetics

authors： Royer B,Jullien V,Guardiola E,Heyd B,Chauffert B,Kantelip JP,Pivot X

更新日期：2009-01-01 00:00:00

abstract：:The half-life of a drug, which expresses a change in concentration in units of time, is perhaps the most easily understood pharmacokinetic parameter and provides a succinct description of many concentration-time profiles. The calculation of a half-life implies a linear, first-order, time-invariant process. No drug per...

journal_title：Clinical pharmacokinetics

authors： Wright JG,Boddy AV

更新日期：2001-01-01 00:00:00

abstract：INTRODUCTION:Because the multimodal antidepressant vortioxetine is likely to be coadministered with other central nervous system (CNS)-active drugs, potential drug-drug interactions warrant examination. OBJECTIVE:These studies evaluated whether there are pharmacokinetic and/or pharmacodynamic interactions between vort...

journal_title：Clinical pharmacokinetics

authors： Chen G,Nomikos GG,Affinito J,Zhao Z

更新日期：2016-09-01 00:00:00

abstract：:The effects of anaesthesia and surgery on the pharmacokinetics of ketobemidone were studied in 12 patients. Plasma ketobemidone concentrations were assayed with a mass-fragmentographic method. The peroperative Vd(area) was 5.9 +/- 2.6L/kg and the terminal half-life was 3.9 +/- 1.7 h. In the postoperative period Vd(are...

journal_title：Clinical pharmacokinetics

authors： Tamsen A,Bondesson U,Dahlström B,Hartvig P

更新日期：1982-05-01 00:00:00

abstract：:The classic approach to describe the pharmacological response to a drug is to analyse its concentration-effect relationship, using a variety of possible models such as maximum effect (Emax) models or sigmoid Emax models. The aim of this review is to discuss an alternative way of describing the pharmacological effect i...

journal_title：Clinical pharmacokinetics

authors： Alván G,Paintaud G,Wakelkamp M

更新日期：1999-05-01 00:00:00

abstract：:Fluorouracil is used clinically against various solid tumours. Both fluorouracil toxicity and pharmacokinetics vary highly within and between individuals. The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a ...

journal_title：Clinical pharmacokinetics

authors： Ploylearmsaeng SA,Fuhr U,Jetter A

更新日期：2006-01-01 00:00:00

abstract：:Aminoglycoside antibiotics are very important in the treatment of Gram-negative infections and as synergistic agents for the treatment of staphylococcal and streptococcal (group B streptococci and enterococci) infections. However, these agents have a narrow therapeutic index. Thus, a number of new antibiotics have bee...

journal_title：Clinical pharmacokinetics

authors： Bertino JS Jr,Rodvold KA,Destache CJ

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bosentan is a competitive antagonist on endothelin receptor A and B (ETA and ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependen...

journal_title：Clinical pharmacokinetics

authors： Volz AK,Krause A,Haefeli WE,Dingemanse J,Lehr T

更新日期：2017-12-01 00:00:00

abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

journal_title：Clinical pharmacokinetics

authors： Scheen AJ

更新日期：2014-04-01 00:00:00

abstract：:This review describes the pharmacokinetics of the major drugs used for the treatment of inflammatory bowel disease. This information can be helpful for the selection of a particular agent and offers guidance for effective and well tolerated regimens. The corticosteroids have a short elimination half-life (t1/2beta) of...

journal_title：Clinical pharmacokinetics

authors： Schwab M,Klotz U

更新日期：2001-01-01 00:00:00